Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

RCT (n=304) found improved progression free survival with daratumumab plus pomalidomide and dexamethasone vs pomalidomide and dexamethasone alone at median follow up of 16.9 months (12.4 vs 6.9 months, HR 0.63, 95%CI 0.47-0.85).

The Lancet Oncology